The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry.
 
Oliver Gautschi
No Relationships to Disclose
 
Juergen Wolf
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Julie Milia
No Relationships to Disclose
 
Thomas Filleron
No Relationships to Disclose
 
David Paul Carbone
Employment - James Cancer Center
Consulting or Advisory Role - Bayer; Biothera; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Merck; Novartis; Peregrine Pharmaceuticals; Pfizer; Synta; Synta
Research Funding - Bristol-Myers Squibb
 
D. Ross Camidge
No Relationships to Disclose
 
Jin-Yuan Shih
No Relationships to Disclose
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Boehringer Ingelheim; Clovis Oncology; Genentech; Merck; Pfizer
 
Florian Cabillic
No Relationships to Disclose
 
Nir Peled
Honoraria - AstraZeneca; Bristol-Myers Squibb; Lilly; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Early detection of lung cancer by exhaled breath technology (Inst); Radiation technique (Inst); Radiosensitizier (Inst)
 
Michel Van Den Heuvel
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Dwight Hall Owen
No Relationships to Disclose
 
Mark G. Kris
Consulting or Advisory Role - ARIAD; Array BioPharma; AstraZeneca; Clovis Oncology; Daiichi Sankyo; Genentech/Roche; Pfizer; Threshold Pharmaceuticals
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst)
 
Pasi A. Janne
No Relationships to Disclose
 
Benjamin Besse
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); GlaxoSmithKline (Inst); Inivata (Inst); Lilly (Inst); Onxeo (Inst); ose pharma (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Novartis; Pfizer; Pierre Fabre; Roche
 
Byoung Chul Cho
Honoraria - AstraZeneca; Novartis
Consulting or Advisory Role - AstraZeneca (Inst); Novartis (Inst)
Speakers' Bureau - AstraZeneca; Novartis
 
Daniel D. Karp
No Relationships to Disclose
 
Rafael Rosell
No Relationships to Disclose
 
Julien Mazieres
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly/ImClone; Novartis; Pfizer; Puma Biotechnology; Roche/Genentech
Research Funding - Puma Biotechnology; Roche
Travel, Accommodations, Expenses - Pfizer; Roche
 
Alexander E. Drilon
Honoraria - Exelixis; Genentech/Roche; Ignyta
Consulting or Advisory Role - AstraZeneca; Exelixis; Genentech/Roche
Speakers' Bureau - Ignyta
Research Funding - Foundation Medicine
Travel, Accommodations, Expenses - AstraZeneca; Exelixis; Genentech/Roche; Ignyta